Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.

Neuro-oncology - 3 May 2024

Arrillaga-Romany Isabel, Lassman Andrew, McGovern Susan L, Mueller Sabine, Nabors Burt, van den Bent Martin, Vogelbaum Michael A, Allen Joshua E, Melemed Allen S, Tarapore Rohinton S, Wen Patrick Y, Cloughesy Timothy

Abstract excerpt

BACKGROUND: H3 K27M-mutant diffuse glioma primarily affects children and young adults, is associated with a poor prognosis, and no effective systemic therapy is currently available. ONC201 (dordaviprone) has previously demonstrated efficacy in patients with recurrent disease. This phase 3 trial evaluates ONC201 in patients with newly diagnosed H3 K27M-mutant glioma. METHODS: ACTION (NCT05580562) is a randomized,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Glioma

Share to Histones

Share to Prognosis

Share to Quality of Life

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 38445964
DOI: 10.1093/neuonc/noae031
PMCID: PMC11066938

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.PMID 38445964Read ↗

Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.Semantic proximity Read ↗

H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions.Semantic proximity Read ↗

ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.Semantic proximity Read ↗

Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.Semantic proximity Read ↗

Clinical efficacy and predictive biomarkers of ONC201 in H3 K27M-mutant diffuse midline gliomaSemantic proximity Read ↗

Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.Semantic proximity Read ↗

Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma.Semantic proximity Read ↗

[Diffuse midline glioma].Semantic proximity Read ↗

Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.Semantic proximity Read ↗

Prognostic Indicators for H3K27M-Mutant Diffuse Midline Glioma: A Population-Based Retrospective Surveillance, Epidemiology, and End Results Database Analysis.Semantic proximity Read ↗

Adult diffuse intrinsic pontine glioma: clinical, radiological, pathological, molecular features, and treatments of 96 patients.Semantic proximity Read ↗

Demonstrated efficacy and mechanisms of sensitivity of ONC201: H3K27M-mutant diffuse midline glioma in the spotlight.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.